Doses studied
CJC-1295 Ipamorelin Dosage in Research Context
What was administered, to which species, by which route — recorded as data of record, never as a protocol to follow.
Read this first
This page records what the CJC-1295 Ipamorelin dosage literature actually measured, and nothing more. It is not a how-to, it carries no human protocol, and it never tells a reader to take anything. The numbers below are reported the way a monograph reports them: studied at this amount, in this species, by this route. Two facts shape everything here. First, much of the dose data comes from rats, and there is no validated human dosing for ipamorelin or for the fixed combination. Second, the two components behave very differently in time — CJC-1295 with DAC lasts days, while ipamorelin clears in hours — so a single "dose" of the pair is really two different exposures stacked together. Where human data exists, it comes from early pharmacokinetic studies of CJC-1295 alone, not from anyone's stack.
Cjc 1295 ipamorelin dosage
In the published record, cjc 1295 ipamorelin dosage is best read as two separate single-component stories rather than one combined regimen, because the combination has no trial of its own. For the CJC-1295 (DAC) half, human Phase 1 pharmacokinetic work studied ascending single and multiple subcutaneous doses of 30 to 60 µg/kg (with the broader program spanning up to roughly 90 µg/kg), establishing the multi-day GH and IGF-1 profile [1]. For the ipamorelin half, the dose data is rodent: 100 µg/kg three times daily in bone studies [11], a dose-dependent subcutaneous series for longitudinal bone growth [9], and 0.01 to 1 mg/kg intravenously for gut-motility work [10], with roughly 1 µg/kg plateauing the GH response in rodent models. No validated human ipamorelin dose has been published. These are research observations, not instructions.
Routes studied
The routes appearing in the literature are subcutaneous (the dominant route for the human CJC-1295 PK work [1] and most rodent ipamorelin studies), intravenous (the human synergy study used IV boluses [3], as did rodent gut-motility work [10]), continuous subcutaneous infusion by osmotic minipump in rodent models, and intranasal in ipamorelin pharmacokinetic studies in rats [8]. Each route is recorded as it appeared in a study. None is presented as a recommended administration method for any person.
Mod grf 1-29
The distinction between CJC-1295 with DAC and mod grf 1-29 is the single most important thing to get right about the GHRH half. Mod GRF (1-29) is simply CJC-1295 without DAC — the 29-amino-acid modified GHRH fragment with no albumin-binding moiety. Without DAC, it is cleared in minutes (on the order of native GRF(1-29), roughly 30 minutes), producing a short, pulsatile GHRH signal rather than the multi-day exposure of the DAC form [5]. The two are often confused under the single label "CJC-1295," but they behave entirely differently in time: DAC for days, Mod GRF (1-29) for minutes. Any reading of the literature that blurs them will misstate the pharmacokinetics.
Half-life in the research record
Half-life is where the mismatch is starkest. CJC-1295 with DAC runs roughly six to eight days in humans (albumin-bound, with peptide detectable beyond 72 hours in rats) [1] [5]. CJC-1295 without DAC — Mod GRF (1-29) — runs on the order of minutes to about 30 minutes, because DPP-IV (a blood enzyme) cleaves it quickly [5]. Ipamorelin runs under about two hours in rodent plasma, with the peak GH response near 40 minutes and no validated human half-life published [8]. Pairing a days-long agent with an hours-long one is the defining pharmacokinetic feature of the combination — and the reason its net GH exposure for any given schedule remains uncharacterized.
Handling and stability (laboratory context)
In a laboratory-handling context, lyophilized (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water — sterile water containing 0.9% benzyl alcohol as a preservative — aqueous peptide solutions are kept refrigerated at 2 to 8 °C and degrade over weeks, chiefly through asparagine deamidation; degradation products can be markedly less potent. Agitation and repeated freeze-thaw are avoided. GHRH analogues undergo DPP-IV cleavage in plasma; CJC-1295's amino-acid substitutions and its DAC were engineered specifically to resist that degradation [5]. This is standard handling information, recorded for completeness, not an instruction to prepare or administer anything.